Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Hedge Funds Look for Rare IPO to Extend Biopharma Rally Stephen Taub For Members Only Biopharma Hedge Funds Gain as Dealmaking Accelerates Stephen Taub Global Equities: One-Country Bias Doesn’t Always Pay Sponsored by Schroders